EUVIMEDEUVIMED entdecken
Crossref

Pharmacogenetics of Trastuzumab Review of literature

Ahmed Salih Sahib, Dunia Abd AL Kareem Ali

Journal of Healthcare · 27.09.2026 · 7 (1) · 175-180

DOI: 10.36959/569/479 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Healthcare, online erschienen am 27.09.2026. Verfasst von Ahmed Salih Sahib und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Trastuzumab (Herceptin) is a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2), improving survival rates in patients with HER2-positive breast cancer. Despite its efficacy, treatment responses vary widely among patients, with approximately 23% of early-stage HER2-positive breast cancer patients experiencing no response or recurrence within a decade. This review explores the pharmacogenetic landscape influencing trastuzumab efficacy, focusing on genetic polymorphisms that affect drug metabolism and therapeutic outcomes. Key genetic factors, including variations in the FCGR3A, TP53, HER2, BARD1, FGFR1, MDM2, and ATM genes, are examined for their roles in modulating the immune response and resistance to therapy. Understanding these genetic influences is crucial for optimizing trastuzumab treatment strategies and personalizing therapy to enhance patient outcomes in HER2-positive breast cancer.

Zitieren

APA

Sahib, A. S., & Ali, D. A. A. K. (2026). Pharmacogenetics of Trastuzumab Review of literature. Journal of Healthcare, 7(1), 175-180. https://doi.org/10.36959/569/479

Vancouver

Sahib AS, Ali DAAK. Pharmacogenetics of Trastuzumab Review of literature. Journal of Healthcare. 2026;7(1):175-180. doi:10.36959/569/479

BibTeX
@article{Sahib2026,
  author = {Sahib, Ahmed Salih and Ali, Dunia Abd AL Kareem},
  title = {Pharmacogenetics of Trastuzumab Review of literature},
  journal = {Journal of Healthcare},
  year = {2026},
  volume = {7},
  number = {1},
  pages = {175--180},
  doi = {10.36959/569/479}
}
Kostenlos starten →